GTG Genetic Technologies Limited

Genetic Technologies Limited ("GTG") (NASDAQ:GENE) (ASX:GTG) is pleased to announce that it has now appointed the law firm of Doralt Seist Csoklich to help further expand the GTG licensing program in Europe. This firm, based in Vienna, Austria will especially focus on new licensing opportunities in the German speaking countries of Germany, Austria and Switzerland. This appointment follows similar recent announcements concerning the appointment of PatentBridge LLC on the U.S. west coast, Dickstein Shapiro Morin & Oshinsky LLP on the U.S. east coast and SJ Berwin in London. This latest appointment follows market research by GTG which identified a significant number of biotechnology firms based in Germany, Austria and Switzerland, who would benefit from taking a license to the GTG non-coding patents. About the GTG non-coding patents. The GTG non-coding patents are relevant to the current and intended activities of many biotechnology companies and research teams world-wide. The patents fall into two families -- non-coding analysis and non-coding mapping, and the patents are issued in all 24 countries in which they were originally filed. GTG has successfully settled six legal challenges to the patents on terms favourable to GTG, and GTG is now focussed on maximizing its licensing opportunities during the next 10 years, before these patents expire. GTG has so far approved 31 licenses to these patents, 26 of them to commercial entities, for a total consideration of approximately A$53 million. GTG has meanwhile identified numerous additional parties who would benefit from a license to the GTG non-coding patents. Accordingly, GTG continues to apply increasing resources to this global out-licensing program. About Doralt Seist Csoklich. This firm provides legal counselling across a wide range of business activities, including trans-border transactions. One partner, Dr. Christoph Leitgeb, has both a legal degree and also a PhD in molecular genetics, and with his extensive experience in patent law and licensing, is expected to take an active role in assisting the GTG licensing program in the German speaking countries. About Genetic Technologies Limited Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. Its three-pronged business strategy includes: 1) the global commercialization of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business in Australia; and, 3) the commercialization of its various research and development projects aimed at generating further intellectual property of global commercial significance. This announcement may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as "should", "expects", "anticipates", "estimates", "believes" or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies' current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.